Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors

Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular carcinoma (HCC). Inhibition of RAF kinases can induce a dose-dependent “paradoxical” upregulation of the downstream mitogen-activated protein kinase (MAPK) pathway in cancer cells. It is unknown whether “paradoxical”...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yunching, Liu, Ya-Chi, Sung, Yun-Chieh, Ramjiawan, Rakesh R., Lin, Ts-Ting, Chang, Chih-Chun, Jeng, Kuo-Shyang, Chang, Chiung-Fang, Liu, Chun-Hung, Gao, Dong-Yu, Hsu, Fu-Fei, Duyverman, Annique M., Kitahara, Shuji, Huang, Peigen, Dima, Simona, Popescu, Irinel, Flaherty, Keith T., Zhu, Andrew X., Bardeesy, Nabeel, Jain, Rakesh K., Benes, Cyril H., Duda, Dan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343435/
https://www.ncbi.nlm.nih.gov/pubmed/28276530
http://dx.doi.org/10.1038/srep44123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343435/
https://www.ncbi.nlm.nih.gov/pubmed/28276530
http://dx.doi.org/10.1038/srep44123

Ejemplares similares